Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Docetaxel in Relapsed Squamous Cell Lung Cancer
NCT02536495Phase 2Withdrawn
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in squamous cell carcinoma of the lung (LSCC). Planned start Sep 2015; status: withdrawn.
02
Drugs
selinexor
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02536495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536495.